Document:

<PAGE>

                                                                    EXHIBIT 10.2

                                 FIRST AMENDMENT

                                       TO

                             JOINT VENTURE AGREEMENT

            THIS FIRST AMENDMENT TO JOINT VENTURE AGREEMENT, effective as of
June 30, 2005 (this "AMENDMENT"), is made by and among Bridgetech Holdings
International, Inc., a Delaware corporation ("BRIDGETECH"), and Amcare Labs
International, Inc., a Delaware corporation ("AMCARE").

            WHEREAS, Bridgetech and Amcare are parties to that certain Joint
Venture Agreement, effective as of April 10, 2005 (the "JOINT VENTURE
AGREEMENT");

            WHEREAS, the parties hereto desire to amend the Joint Venture
Agreement to extend the period of time for closing;

            NOW, THEREFORE, in consideration of the premises and the mutual
representations, warranties, covenants and agreements set forth in this
Amendment, the parties hereto agree as follows:

            1. Defined Terms; Definitions. Capitalized terms that are used but
not defined in this Amendment shall have the meanings ascribed to such terms in
the Joint Venture Agreement.

            2. Effective Time of Amendment. This Amendment and the terms and
provisions hereof shall be effective as of the date hereof.

            3. Amendment to Section 2.2(d). Section 2.2(d) of the Joint Venture
Agreement is hereby amended by deleting the date "June 30, 2005" and replacing
it with the date "July 31, 2005".

            4. Binding Effect. This Amendment shall be binding upon and inure to
the benefit of the parties hereto and their heirs, executors, administrators,
successors and permitted assigns. The Joint Venture Agreement, as amended by
this Amendment, shall remain in full force and effect following the
effectiveness of this Amendment in accordance with Section 2 hereof.

            5. Restatement of Joint Venture Agreement. The terms and provisions
of this Amendment may be incorporated into an amended and restated version of
the Joint Venture Agreement that restates, but does not further amend, the Joint
Venture Agreement as amended by this Amendment.

            6. Counterparts. This Amendment may be executed simultaneously in
two or more counterparts, any one of which need not contain the signatures of
more than one party, but all of such counterparts taken together shall
constitute one and the same Amendment. A facsimile copy of a party's signature
to this Amendment shall be deemed to be an original.

            7. Governing Law. This Amendment shall be deemed to be made in, and
in all respects shall be interpreted, construed and governed by and in
accordance with the laws of the State of Delaware.

<PAGE>

            IN WITNESS WHEREOF, the parties hereto have duly executed and
delivered this Amendment as of the date first written above.

                                         BRIDGETECH HOLDINGS INTERNATIONAL, INC.

                                         By:        /s/ Thomas C. Kuhn III
                                             -----------------------------------
                                             Name:  Thomas C. Kuhn III
                                             Title: Executive Vice President
                                                    and Chief Financial Officer

                                         AMCARE LABS INTERNATIONAL, INC.

                                         By:       /s/ Mohan Chellappa
                                            ------------------------------------
                                            Name:  Mohan Chellappa
                                            Title: President

                                       2<PAGE>

                                                                    EXHIBIT 10.3

                                SECOND AMENDMENT

                                       TO

                             JOINT VENTURE AGREEMENT

            THIS SECOND AMENDMENT TO JOINT VENTURE AGREEMENT, effective as of
July 25, 2005 (this "AMENDMENT"), is made by and among Bridgetech Holdings
International, Inc., a Delaware corporation ("BRIDGETECH"), and Amcare Labs
International, Inc., a Delaware corporation ("AMCARE").

            WHEREAS, Bridgetech and Amcare are parties to that certain Joint
Venture Agreement, effective as of April 10, 2005 (the "JOINT VENTURE
AGREEMENT");

            WHEREAS, the parties hereto desire to amend the Joint Venture
Agreement;

            NOW, THEREFORE, in consideration of the premises and the mutual
representations, warranties, covenants and agreements set forth in this
Amendment, the parties hereto agree as follows:

            1. Defined Terms; Definitions. Capitalized terms that are used but
not defined in this Amendment shall have the meanings ascribed to such terms in
the Joint Venture Agreement.

            2. Effective Time of Amendment. This Amendment and the terms and
provisions hereof shall be effective as of the date hereof.

            3. Amendment to Section 1.1(b). Section 1.1(b) of the Joint Venture
Agreement is hereby amended by deleting the word "China" and replacing it with
the words "the Territory".

            4. Amendment to Section 3.5(e). The first sentence of Section 3.5(e)
of the Joint Venture Agreement is hereby amended by deleting the words "Newco's
financial accounts" and replacing them with the words "The financial accounts of
Newco1 and Newco2".

            5. Amendment to Section 3.5(g). Section 3.5(g) of the Joint Venture
Agreement is hereby amended by (i) deleting the first word of Section 3.5(g),
which is the word "Any", and replacing it with the words "Subject to Section
3.3(c)(vii), any" and (ii) deleting the words "subject to Section 3.3(e)(vii),"
from clause (ii) of such sentence.

            6. Amendment to Section 4.2(a). Section 4.2(a) of the Joint Venture
Agreement is hereby amended by adding the words "and their Affiliates"
immediately following the words "BRIDGETECH and AMCARE".

            7. Amendment to Section 12.11. Section 12.11 of the Joint Venture
Agreement is hereby amended by adding the following sentence to the end of
Section 12.11: "A facsimile copy of a party's signature to this Agreement and
any documents to be executed or delivered in connection herewith shall be deemed
to be an original signature."

<PAGE>

            8. Binding Effect. This Amendment shall be binding upon and inure to
the benefit of the parties hereto and their heirs, executors, administrators,
successors and permitted assigns. The Joint Venture Agreement, as amended by
this Amendment, shall remain in full force and effect following the
effectiveness of this Amendment in accordance with Section 2 hereof.

            9. Restatement of Joint Venture Agreement. The terms and provisions
of this Amendment may be incorporated into an amended and restated version of
the Joint Venture Agreement that restates, but does not further amend, the Joint
Venture Agreement as amended by this Amendment.

            10. Counterparts. This Amendment may be executed simultaneously in
two or more counterparts, any one of which need not contain the signatures of
more than one party, but all of such counterparts taken together shall
constitute one and the same Amendment. A facsimile copy of a party's signature
to this Amendment shall be deemed to be an original.

            11. Governing Law. This Amendment shall be deemed to be made in, and
in all respects shall be interpreted, construed and governed by and in
accordance with the laws of the State of Delaware.

                         (Signatures on following page.)

                                       2
<PAGE>

            IN WITNESS WHEREOF, the parties hereto have duly executed and
delivered this Amendment as of the date first written above.

                                         BRIDGETECH HOLDINGS INTERNATIONAL, INC.

                                         By:        /s/ Thomas C. Kuhn III
                                             -----------------------------------
                                             Name:  Thomas C. Kuhn III
                                             Title: Executive Vice President
                                                    and Chief Financial Officer

                                         AMCARE LABS INTERNATIONAL, INC.

                                         By:       /s/ Mohan Chellappa
                                            ------------------------------------
                                            Name:  Mohan Chellappa
                                            Title: President

                                       3<PAGE>

                                                                    EXHIBIT 10.4

                              MANAGEMENT AGREEMENT

      THIS MANAGEMENT AGREEMENT (the "Agreement") is entered into as of April
10, 2005, by and among NEWCO1, a Delaware corporation ("NEWCO"), and AMCARE LABS
INTERNATIONAL, INC., a Delaware corporation (the "CONSULTANT").

      WHEREAS, Consultant and Bridgetech Holdings International Inc. have
entered into that certain Joint Venture Agreement, with an effective date of
April 10, 2005 (the "JOINT VENTURE AGREEMENT");

      WHEREAS, Consultant is in the business of providing laboratory medicine
and pathology services in select global markets and has experience with
strategic planning, business administration and other management skills and
services related thereto;

      WHEREAS, Newco will require Consultant's special advisory skills and
services in connection with its general business operations;

      WHEREAS, Consultant is willing to provide such advisory services to Newco
through an advisory committee to be formed by Consultant for such specific
purpose; and

      WHEREAS, Consultant also desires to assist Newco with the development of a
marketing plan and to license certain trademarks to Newco;

      NOW, THEREFORE, in consideration of the mutual promises contained herein,
the parties hereto, intending to be legally bound, do hereby agree as follows:

      1. Defined Terms. Capitalized terms not otherwise defined herein shall
have the meanings assigned to them in the Joint Venture Agreement.

      2. Engagement; Services to be Performed. Newco hereby engages the
Consultant for the Term (as hereinafter defined) and upon the terms and
conditions set forth herein to provide consulting and advisory services to
Newco, to the extent reasonably requested by Newco (the "SERVICES"). These
Services will be as more fully described on Schedule 2 hereto. In consideration
of the remuneration herein specified, Consultant accepts such engagement and
agrees to perform the Services as specified herein.

      3. Advisory Committee. Consultant acknowledges that Newco may form an
Advisory Committee for the purpose of providing strategic and other guidance to
Newco (the "ADVISORY COMMITTEE"). Consultant hereby agrees, to the extent
requested by Newco and for no additional consideration, to (i) assist Newco in
identifying candidates to serve on the Advisory Committee and (ii) make
available [ONE (1)] employee of Consultant, to be agreed upon by Consultant and
Newco, to serve on the Advisory Committee.

      4. Compensation; Expense Reimbursement.

                  (a) In consideration of the Services and the other matters set
forth herein, Newco shall pay Consultant a quarterly fee (hereinafter, the
"Management Fee") equal to 5.0% of the

<PAGE>

gross revenues of Newco for such quarter, which Management Fee shall be paid to
the Consultant by Newco in cash on or before the [THIRTIETH (30TH)] day
following the end of the calendar quarter.

                  (b) In addition to the Management Fee, Newco shall reimburse
Consultant for all reasonable out-of-pocket expenses incurred by Consultant in
connection with Consultant's performance of such services (other than the
Services) that may be requested by Newco from time-to-time during the Term,
including, without limitation, reasonable travel, lodging and similar
out-of-pocket costs reasonably incurred by it in connection with or on account
of its performance of such services for Newco. Consultant must obtain the
approval of Newco for the incurrence of any reimbursable costs in excess of
$1000 (which approval shall not be unreasonably withheld). Reimbursement shall
be made only upon presentation to Newco by the Consultant of reasonably itemized
documentation therefor.

                  (c) Consultant hereby acknowledgtes that it has received a
payment of $30,000 from Newco (or Bridgetech Holdings International, Inc.) as an
advance payment of future Management Fees that may become payable pursuant to
Section 4(a) above. Newco and Consutlant hereby agree that Newco shall not be
obligated to pay any quarterly Management Fees to Consultant pursuant to Section
4(a) until the aggregate amount of Management Fees earned by the Consultant
pursuant to Section 4(a) exceeds $30,000.

      5. License.

                  (a) Consultant hereby grants to Newco a non-exclusive,
non-transferable, royalty-free license or sub-license, as applicable, (the
"License") to use the trademarks identified and depicted on Schedule 5 hereto
(the "Marks") during the Term (and any extensions thereof).

                  (b) Newco shall use the Marks only in connection with its
advertising, promotional activities, website, corporate presentations and as may
be otherwise agreed by Consultant.

                  (c) Consultant hereby represents and warrrants to Newco that
Consultant is (i) the sole and exclusive owner of the Marks or (ii) has a valid
and existing license to such Marks with a right to sub-license such Marks to
Newco as provided herein.

                  (d) Consultant hereby acknowledges and agrees that Newco shall
be entitled to advertise, publicize and otherwise represent to third parties the
fact that Newco is managed by Consultant, which is affiliated with Johns Hopkins
International Medical Laboratories, in any correspondence, communications
(verbal, printed or otherwise), promotional and marketing materials or
otherwise. To the extent necessary to accomplish the foregoing provisions,
Consultant will license or sublicense any relevant intellectual property rights
to Newco. Consultant hereby represents and warrants to Newco that Consultant is
party to a written agreement with Johns Hopkins International Medical
Laboratories pursuant to which Consultant is designated as an "affiliate" of
Johns Hopkins International Medical Laboratories. Such agreement is a legal,
valid and binding obligation with respect to each of Consultant and Johns
Hopkins International Medical Laboratories. Neither Johns Hopkins Medical
Laboratories nor Consultant is in breach of or in default under such agreement.
During the Term, Consultant shall notify Newco in writing immediately upon the
termination or expiration of such agreement or any amendment thereof or default
thereunder that results or could reasonably be expected to result in Consultant
no longer being an affiliate of Johns Hopkins International Medical
Laboratories. Consultant further represents and warrants to Newco that
Consultant has a valid license and right to sublicense to Newco and Marks that
are owned by Johns Hopkins International Medical Laboratories.

                                     - 2 -
<PAGE>

      6. Term. Unless earlier terminated pursuant to the Joint Venture
Agreement, the engagement hereunder shall be for a term commencing on the date
hereof and expiring on the tenth anniversary hereof (the "TERM"). Upon
expiration of the Term, this Agreement shall automatically extend for successive
periods of one (1) year, unless either party shall give notice to the other
Party at least ninety (90) days prior to the end of the Term (or any annual
extension thereof) indicating that it does not intend to renew this Agreement.
Upon termination of this Agreement or expiration of the Term (including all
annual extensions thereof), the parties shall have no further obligations
hereunder other than the obligation to pay any accrued but unpaid fees for
Services performed by Consultant prior to the effective date of such
termination.

      7. Binding Effect. This Agreement shall be binding on and inure to the
benefit of the Parties and their respective successors and permitted assigns.

      8. Assignment. This Agreement shall not be assigned by either Party
without the prior written consent of the other Party, not to be unreasonably
delayed or withheld, and any purported such assignment without such consent
shall be void.

      9. Notices And Other Communications.

                  (a) Each notice, communication and delivery under this
Agreement (i) shall be made in writing signed by the Party making the same, (ii)
shall specify the Section of this Agreement pursuant to which it is given, (iii)
shall be given either in person or by telecopier, effective upon such delivery
or the confirmed transmission and (iv) if not given in person, shall be sent to
the applicable Party at the address set forth below (or at such other address as
the applicable Party may furnish to the other Party pursuant to this subsection)
by international courier delivery service, effective upon the 7th business day
after such notice is deposited, delivery charges pre-paid, with such
international courier delivery service. Each Party's notice information is as
follows:

             NEWCO:        c/o Bridgetech Holdings International, Inc.
                           777 S. Highway 101, Suite 215
                           Solana Beach, California 92075
                           USA
                           Attn: Thomas C. Kuhn III
                           Phone: 619-342-7440
                           Fax:  619-342-7497

             AMCARE:       AmcareLabs International, Inc
                           5801 Smith Avenue, Suite 305
                           Baltimore, Maryland 21207
                           USA
                           Attn: Mohan Chellappa
                           Phone: 410-735-6558
                           Fax:  410-735-6552

                  (b) Either Party may modify any information specified in this
Section 9 by giving written notice to the other Party.

                                     - 3 -
<PAGE>

                  (c) All written communications made as provided in Section 9
shall be deemed given upon receipt by the Party to which it is addressed, which,
in the case of facsimile, shall be deemed to occur by the close of the business
day in the place of receipt on which the same is transmitted or such earlier
time as is confirmed by the receiving Party.

      10. Severability. If any term or provision of this Agreement, or the
application thereof to any person or circumstance, shall to any extent be
contrary to any applicable law or regulation or otherwise invalid or
unenforceable, the remainder of this Agreement or the application of such term
or provision to persons or circumstances other than those as to which it is
contrary, invalid or unenforceable shall not be affected thereby and, to the
extent consistent with the overall intent of this Agreement taken as a whole,
shall be enforced to the fullest extent permitted by applicable law and
regulation.

      11. No Waiver. No waiver by either Party of any one or more defaults by
the other Party in the performance of any of the provisions of this Agreement
shall operate or be construed as a waiver of any other default or defaults
whether of a like kind or different nature. No delay by either Party in the
enforcement of any of its rights under this Agreement shall be deemed to be a
waiver of such rights.

      12. Relationship between the Parties. Except to the extent provided in the
Joint Venture Agreement, nothing in this Agreement shall create or be deemed to
create a partnership or joint venture between the Parties and except to the
extent expressly specified in this Agreement, no Party will or is entitled to
act as agent for any other Party.

      13. No Third Party Beneficiaries. Except to the extent provided in the
Joint Venture Agreement, this Agreement confers no rights whatsoever upon any
person other than the Parties hereto and shall not create, or be interpreted as
creating, any standard of care, duty or liability to any person not a Party
hereto.

      14. Governing Law. This Agreement will be governed by the laws of Delaware
except as specifically provided in such documents, without regard to principles
of conflict of laws.

      15. Certain Rules of Construction. The following rules of construction
will apply throughout this Agreement:

                  (a) Headings. Any headings used in this Agreement are for the
purpose of convenience only and shall not affect the meaning or interpretation
of the agreement or document in question.

                  (b) Words of Inclusion. The word "including" will not be
construed to be a term of limitation, so that references to "included" matters
or items will be regarded as illustrative and will not be interpreted as a
limitation on, or an exclusive listing of, the matters or items referred to.

                  (c) Singular and Plural Forms; Genders. Whenever the context
so requires, the singular includes the plural and the plural includes the
singular, and the gender of any pronoun includes the other genders.

      16. Counterparts. This Agreement may be executed by each Party upon a
separate copy, and in several counterparts, each of which will be deemed to be
an original.

                     [Signatures appear on following page.]

                                     - 4 -
<PAGE>

DULY EXECUTED and delivered by the parties as of the date first above appearing.

                                         NEWCO

                                         By:    /s/ Thomas C. Kuhn III
                                                --------------------------------
                                         Name:  Thomas C. Kuhn III
                                         Title: EVP and CFO

                                         AMCARE LABS INTERNATIONAL, INC.

                                         By:    /s/ Mohan Chellappa
                                                --------------------------------
                                         Name:  Mohan Chellappa
                                         Title: President

                                     - 5 -
<PAGE>

                                   SCHEDULE 2

                                    SERVICES

- Protocols
- Procedures
- Oversight
- Advice

                                     - 6 -
<PAGE>

                                   SCHEDULE 5

                                      MARKS

[AMCARE NAME AND LOGO]

[JHI NAME AND LOGO]

                                     - 7 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00095-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00095-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00095-of-00352.parquet"}]]